Literature DB >> 16227991

A crucial role for antigen-presenting cells and alloantigen expression in graft-versus-leukemia responses.

Pavan Reddy1, Yoshinobu Maeda, Chen Liu, Oleg I Krijanovski, Robert Korngold, James L M Ferrara.   

Abstract

Graft-versus-leukemia (GVL) response after allogeneic bone marrow transplantation (BMT) represents one of the most potent forms of immunotherapy against malignant diseases. Antigen-presenting cells (APCs) are crucial for the induction of graft-versus-host disease (GVHD), the most serious complication of allogeneic BMT, but their role in GVL responses is unclear. Using a series of clinically relevant mouse GVL tumor models, we found that APCs and alloantigen expression on tumors are crucial for GVL. Moreover, APCs of host origin predominated in GVL responses although donor APCs contributed as the acuity of tumor burden decreased.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16227991     DOI: 10.1038/nm1309

Source DB:  PubMed          Journal:  Nat Med        ISSN: 1078-8956            Impact factor:   53.440


  109 in total

1.  Alloantigen expression on non-hematopoietic cells reduces graft-versus-leukemia effects in mice.

Authors:  Shoji Asakura; Daigo Hashimoto; Shuichiro Takashima; Haruko Sugiyama; Yoshinobu Maeda; Koichi Akashi; Mitsune Tanimoto; Takanori Teshima
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

Review 2.  Dendritic cells and regulation of graft-versus-host disease and graft-versus-leukemia activity.

Authors:  Elizabeth O Stenger; Hēth R Turnquist; Markus Y Mapara; Angus W Thomson
Journal:  Blood       Date:  2012-03-07       Impact factor: 22.113

3.  Induction of acute GVHD by sex-mismatched H-Y antigens in the absence of functional radiosensitive host hematopoietic-derived antigen-presenting cells.

Authors:  Tomomi Toubai; Isao Tawara; Yaping Sun; Chen Liu; Evelyn Nieves; Rebecca Evers; Thea Friedman; Robert Korngold; Pavan Reddy
Journal:  Blood       Date:  2011-11-18       Impact factor: 22.113

4.  Recipient lymphocyte infusion in MHC-matched bone marrow chimeras induces a limited lymphohematopoietic host-versus-graft reactivity but a significant antileukemic effect mediated by CD8+ T cells and natural killer cells.

Authors:  Lien De Somer; Ben Sprangers; Sabine Fevery; Omer Rutgeerts; Caroline Lenaerts; Louis Boon; Mark Waer; An D Billiau
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

5.  Alternative mechanisms that mediate graft-versus-host disease in allogeneic hematopoietic cell transplants.

Authors:  James W Young
Journal:  J Clin Invest       Date:  2020-09-01       Impact factor: 14.808

6.  Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.

Authors:  Ronjon Chakraverty; Hyeon-Seok Eom; Jessica Sachs; Jennifer Buchli; Pete Cotter; Richard Hsu; Guiling Zhao; Megan Sykes
Journal:  Blood       Date:  2006-06-06       Impact factor: 22.113

7.  Siglec-G represses DAMP-mediated effects on T cells.

Authors:  Tomomi Toubai; Corinne Rossi; Katherine Oravecz-Wilson; Cynthia Zajac; Chen Liu; Thomas Braun; Hideaki Fujiwara; Julia Wu; Yaping Sun; Stuart Brabbs; Hiroya Tamaki; John Magenau; Pang Zheng; Yang Liu; Pavan Reddy
Journal:  JCI Insight       Date:  2017-07-20

Review 8.  Genetically engineered donor T cells to optimize graft-versus-tumor effects across MHC barriers.

Authors:  Arnab Ghosh; Amanda M Holland; Marcel R M van den Brink
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

9.  SHP-1 Acts as a Key Regulator of Alloresponses by Modulating LFA-1-Mediated Adhesion in Primary Murine T Cells.

Authors:  Martin G Sauer; Jessica Herbst; Ulf Diekmann; Christopher E Rudd; Christian Kardinal
Journal:  Mol Cell Biol       Date:  2016-11-28       Impact factor: 4.272

10.  PKCtheta is required for alloreactivity and GVHD but not for immune responses toward leukemia and infection in mice.

Authors:  Javier O Valenzuela; Cristina Iclozan; Mohammad S Hossain; Martin Prlic; Emily Hopewell; Crystina C Bronk; Junmei Wang; Esteban Celis; Robert W Engelman; Bruce R Blazar; Michael J Bevan; Edmund K Waller; Xue-Zhong Yu; Amer A Beg
Journal:  J Clin Invest       Date:  2009-11-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.